Value investing message boards image Log on |  Join ($$) Stock market forums image VF "How To" Guide        Welcome, guest! Learn about guest access                       
ValueForum.com Home
• Related Discussion Forum Messages
As a ValueForum member, this section would contain XLRN message board posts where the ticker symbol XLRN has been mentioned by ValueForum members in posts. Learn more about guest access, and benefits of membership -- we hope you will consider joining ValueForum or trying out our service with a 24 hour trial pass.

• Latest XLRN SEC Filings

Filings Format Description Filing Date File/Film Number
CT ORDER  Documents Confidential treatment order
Acc-no: 9999999997-17-010079 (34 Act)  Size: 14 KB
2017-11-28 001-36065
171224943
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0001179110-17-014159 Size: 5 KB
2017-11-15
3  Documents Initial statement of beneficial ownership of securities
Acc-no: 0001179110-17-014158 Size: 6 KB
2017-11-15
8-K  Documents Current report, item 5.02
Acc-no: 0001280600-17-000057 (34 Act)  Size: 31 KB
2017-11-15 001-36065
171205294
SC 13G/A  Documents [Amend] Statement of acquisition of beneficial ownership by individuals
Acc-no: 0000315066-17-002875 (34 Act)  Size: 9 KB
2017-11-09 005-87630
171192028
10-Q  Documents   Interactive Data Quarterly report [Sections 13 or 15(d)]
Acc-no: 0001280600-17-000055 (34 Act)  Size: 6 MB
2017-11-07 001-36065
171181082
8-K  Documents Current report, items 2.02 and 9.01
Acc-no: 0001280600-17-000054 (34 Act)  Size: 159 KB
2017-11-07 001-36065
171181074
SC 13G/A  Documents [Amend] Statement of acquisition of beneficial ownership by individuals
Acc-no: 0000315066-17-002823 (34 Act)  Size: 9 KB
2017-10-10 005-87630
171128827
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0001179110-17-012763 Size: 6 KB
2017-09-29
SC 13D/A  Documents [Amend] General statement of acquisition of beneficial ownership
Acc-no: 0001144204-17-049480 (34 Act)  Size: 61 KB
2017-09-25 005-87630
171100048
More XLRN SEC Filings


Related news from
Tue, 12 Dec 2017
08:00:00 +0000
Acceleron Pharma Sees RS Rating Climb To 74
Acceleron Pharma shows improving price performance, earning an upgrade to its IBD Relative Strength Rating
Sun, 10 Dec 2017
14:00:00 +0000
Acceleron Announces Updated Results from Ongoing Phase 2 Trials of Luspatercept in Myelodysplastic Syndromes at the 59th Annual Meeting of the American Society of Hematology
Acceleron Pharma Inc. , a leading biopharmaceutical company in the discovery and development of TGF-beta therapeutics to treat serious and rare diseases, today announced preliminary results from the ongoing Phase 2 trials with luspatercept in patients with lower-risk myelodysplastic syndromes at the 59th Annual Meeting of the American Society of Hematology in Atlanta, Georgia.
Thu, 07 Dec 2017
21:28:28 +0000
5 Health Care Stocks Gurus Are Buying
Gurus are investing in these popular stocks
Tue, 05 Dec 2017
12:00:00 +0000
Acceleron to Host Conference Call and Webcast to Review Data Presented at the 59th American Society of Hematology Annual Meeting and Exposition
Acceleron Pharma Inc. will host a conference call and live audio webcast on Monday, December 11, 2017 at 7:00 a.m. EST to review highlights from its Phase 2 clinical presentations at the 59th American Society of Hematology Annual Meeting and Exposition taking place December 9-12, 2017 in Atlanta, Georgia.
Mon, 20 Nov 2017
12:26:00 +0000
Acceleron Pharma, Inc. breached its 50 day moving average in a Bullish Manner : XLRN-US : November 20, 2017
Categories: ETFs Yahoo FinanceGet full CapitalCube analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for Acceleron Pharma, Inc.. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bullish Closing Price above/below 200 Day Moving Average Bullish ... Read more <b>(Read more...)</b>
Thu, 16 Nov 2017
12:10:00 +0000
Corporate News Blog - Loxo Oncology Collaborates with Bayer to Develop and Commercialize Larotrectinib and LOXO-195
Research Desk Line-up: Acceleron Pharma Post Earnings Coverage LONDON, UK / ACCESSWIRE / November 16, 2017 / Pro-Trader Daily takes a look at the latest corporate events and news making the headlines for ...
Wed, 15 Nov 2017
21:01:00 +0000
Acceleron Announces Appointment of Dr. Karen Smith to its Board of Directors and Departure of Terrance McGuire
Acceleron Pharma Inc. today announced the appointment of the experienced biopharmaceutical executive, Karen Smith, M.D., Ph.D., to its board of directors and the departure of Terrance McGuire, effective November 15, 2017.
Tue, 14 Nov 2017
21:01:00 +0000
Acceleron Announces Preclinical Results in Pulmonary Arterial Hypertension at the American Heart Association 2017 Scientific Sessions
Acceleron Pharma Inc. , a leading biopharmaceutical company in the discovery and development of TGF-beta therapeutics to treat serious and rare diseases, today announced new preclinical results with sotatercept in pulmonary arterial hypertension during an oral presentation at the American Heart Association 2017 Scientific Sessions in Anaheim, California.
Fri, 10 Nov 2017
03:46:39 +0000
Edited Transcript of XLRN earnings conference call or presentation 7-Nov-17 1:00pm GMT
Q3 2017 Acceleron Pharma Inc Earnings Call
Thu, 09 Nov 2017
18:23:56 +0000
ETFs with exposure to Acceleron Pharma, Inc. : November 9, 2017
Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Acceleron Pharma, Inc. Here are 5 ETFs with the largest exposure to XLRN-US. Comparing the performance and risk of Acceleron Pharma, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more <b>(Read more...)</b>
Wed, 08 Nov 2017
19:38:27 +0000
Acceleron Pharma, Inc. :XLRN-US: Earnings Analysis: Q3, 2017 By the Numbers : November 8, 2017
Categories: Yahoo FinanceGet free summary analysis Acceleron Pharma, Inc. reports financial results for the quarter ended September 30, 2017. We analyze the earnings along side the following peers of Acceleron Pharma, Inc. – Celgene Corporation, OncoMed Pharmaceuticals, Inc., Amgen Inc., Johnson & Johnson, Pfizer Inc., bluebird bio, Inc. and Shire PLC Sponsored ADR (CELG-US, OMED-US, AMGN-US, JNJ-US, ... Read more <b>(Read more...)</b>
Tue, 07 Nov 2017
12:15:44 +0000
Acceleron reports 3Q loss
On a per-share basis, the Cambridge, Massachusetts-based company said it had a loss of 65 cents. The results exceeded Wall Street expectations. The average estimate of six analysts surveyed by Zacks Investment ...
Mon, 06 Nov 2017
18:23:40 +0000
Acceleron Pharma, Inc. – Value Analysis (NASDAQ:XLRN) : November 6, 2017
Categories: Fundamental Analysis Yahoo FinanceClick here to see latest analysis Capitalcube gives Acceleron Pharma, Inc. a score of 36. Our analysis is based on comparing Acceleron Pharma, Inc. with the following peers – OncoMed Pharmaceuticals, Inc., Amgen Inc., Regeneron Pharmaceuticals, Inc., Celgene Corporation, Pfizer Inc., Shire PLC Sponsored ADR, bluebird bio, Inc., Johnson & Johnson, Sangamo Therapeutics, Inc. and ... Read more <b>(Read more...)</b>
Fri, 03 Nov 2017
12:36:10 +0000
Acceleron Pharma, Inc. breached its 50 day moving average in a Bearish Manner : XLRN-US : November 3, 2017
Categories: ETFs Yahoo FinanceGet full CapitalCube analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for Acceleron Pharma, Inc.. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bearish Closing Price above/below 200 Day Moving Average Bullish ... Read more <b>(Read more...)</b>
Wed, 01 Nov 2017
13:19:00 +0000
Acceleron to Present Clinical Presentations at the 59th American Society of Hematology Annual Meeting and Exposition
Acceleron Pharma Inc. , a leading biopharmaceutical company in the discovery and development of TGF-beta therapeutics to treat serious and rare diseases, today announced that two abstracts have been accepted for presentation at the 59th American Society of Hematology Annual Meeting and Exposition in Atlanta, Georgia on December 9-12, 2017.
Thu, 26 Oct 2017
11:00:00 +0000
Acceleron to Webcast Third Quarter 2017 Financial Results on November 7, 2017
Acceleron Pharma Inc. today announced it will host a webcast and conference call on Tuesday, November 7, 2017 at 8:00 a.m. EST to discuss its third quarter 2017 financial results and provide an update on recent clinical development and corporate activities.
Wed, 25 Oct 2017
16:34:52 +0000
Edited Transcript of XLRN earnings conference call or presentation 8-May-17 12:00pm GMT
Q1 2017 Acceleron Pharma Inc Earnings Call
Wed, 18 Oct 2017
12:36:12 +0000
Options Traders Expect Huge Moves in Acceleron Pharma (XLRN) Stock
Surging level of implied volatility makes Acceleron Pharma (XLRN) stock lucrative to the option traders.
Thu, 12 Oct 2017
19:32:01 +0000
4 Biotech Stocks Initiated At Buy: Acceleron, Tesaro, Mirati, Fate
H.C. Wainwright has initiated bullish coverage of four healthcare stocks headed into the end of 2017. Analyst Edward White explained his positive take on the four stocks in a research note on Thursday. ...
Thu, 05 Oct 2017
11:00:00 +0000
Acceleron Announces Closing of Underwriters’ Option to Purchase Additional Shares
Acceleron Pharma Inc. , a leading biopharmaceutical company in the discovery and development of TGF-beta therapeutics to treat serious and rare diseases, today announced that it has issued 810,810 shares of common stock at the public offering price of $37.00 per share, pursuant to the full exercise of the underwriters’ over-allotment option in connection with the Company’s previously announced public ...



"ValueForum is an active, private, online discussion community for stock & bond market investing. In discussion forums divided into finely grained topics, you will find sophisticated investors trading tips, research, and due diligence on value stocks, income investments, forex, market news, and more. Join in - trade ideas, strategies, current news, via our unique message bulletin boards, stock ratings system, and other online tools specifically geared toward our community."

Random member testimonial: "ValueForum is comprised of a large and growing, diverse, knowledgeable group of investors. The attribute you should appreciate that this wonderful group makes available to you as an incoming member is Generosity. Research, firsthand sector sophistication, source references and sometimes remarkably insightful analyses are given freely by the members so you may do your own due dilligence in making informed investment decisions." more testimonials »

Email / About | Privacy | Terms of Use | How To / FAQ | Msg Ticker | VF Home | My.vf | BDCs.vf | Energy.vf | REITs.vf | TA.vf
 
Nothing in ValueForum.com is intended to be investment advice, nor does it represent the opinion of, counsel
from, or recommendations by ValueForum.com. ©2003 - 2017, Powered in part by Ticker TechnologiesContact Us

Stock Market Investing Forum - Trading Tips & Research - Online Message Boards